Skip to main content

Inmune Bio, Inc 10-Q for FY2026 Q3

Inmune Bio, Inc. (INMB)

10-Q 2026-11-05 For: 2026-09-30
View Original
Added on November 05, 2026

About this 10-Q

Inmune Bio, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

INmune Bio plans to file CORDStrom’s UK Marketing Authorization Application during February 2027 and an FDA Biologics License Application at mid-2027. It reported a $11.4 million nine-month net loss, $16.3 million cash, and substantial doubt about continuing as a going concern. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$4.72M
compared with a net loss of $6.47M a year earlier
Diluted EPS
-$0.17
compared with -$0.24 a year earlier